As for the prognostic value of these markers, Horst et al implied that CD133 might be of the most clinical relevance, while the combined evaluation of CD133, CD44, and CD166 might even be more valuable to separate high-risk from low-risk colorectal cancer cases[42]. The gene discussed is CD44; the disease is colorectal cancer.